<?xml version='1.0' encoding='utf-8'?>
<document id="20508871"><sentence text="Population-based severity, onset and type of drug-drug interactions in prescriptions." /><sentence text="Inappropriate drug combinations occur frequently and may lead to serious adverse events" /><sentence text=" In Iran, drug overdose and interactions are relatively common but rarely reported and are mainly derived from admitted subjects" /><sentence text=" The aim of this study was to determine the prevalence of possible drug-drug interactions via a population database survey in Mashhad, Iran" /><sentence text=" In this survey all prescriptions paid by insurance companies in the period 21rst March 2006 to 20th March 2008 were studied retrospectively" /><sentence text=" Data were gathered from the Division of Rational Use Drug, Food and Drug Vice Chancellor of Mashhad University of Medical Sciences, Iran" /><sentence text=" Drug interactions were categorized based on severity, onset and dynamic/kinetic nature" /><sentence text=" Incidence was calculated based on the number of interactions/1000 prescriptions" /><sentence text=" In total 11,562,808 prescriptions were studied, among which 5% showed interactions" /><sentence text=" Two hundred and four types of potential interactions were detected" /><sentence text=" Belladonna, phenytoin sodium, cimetidine, propranolol hydrochloride, gentamicin, acetylsalicylic acid (ASA), Antacid, theophylline and carbamazepine were the most common medications"><entity charOffset="13-29" id="DDI-PubMed.20508871.s11.e0" text="phenytoin sodium" /><entity charOffset="31-41" id="DDI-PubMed.20508871.s11.e1" text="cimetidine" /><entity charOffset="43-68" id="DDI-PubMed.20508871.s11.e2" text="propranolol hydrochloride" /><entity charOffset="70-80" id="DDI-PubMed.20508871.s11.e3" text="gentamicin" /><entity charOffset="82-102" id="DDI-PubMed.20508871.s11.e4" text="acetylsalicylic acid" /><entity charOffset="104-107" id="DDI-PubMed.20508871.s11.e5" text="ASA" /><entity charOffset="110-117" id="DDI-PubMed.20508871.s11.e6" text="Antacid" /><entity charOffset="119-131" id="DDI-PubMed.20508871.s11.e7" text="theophylline" /><entity charOffset="136-149" id="DDI-PubMed.20508871.s11.e8" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e0" e2="DDI-PubMed.20508871.s11.e0" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e0" e2="DDI-PubMed.20508871.s11.e1" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e0" e2="DDI-PubMed.20508871.s11.e2" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e0" e2="DDI-PubMed.20508871.s11.e3" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e0" e2="DDI-PubMed.20508871.s11.e4" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e0" e2="DDI-PubMed.20508871.s11.e5" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e0" e2="DDI-PubMed.20508871.s11.e6" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e0" e2="DDI-PubMed.20508871.s11.e7" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e0" e2="DDI-PubMed.20508871.s11.e8" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e1" e2="DDI-PubMed.20508871.s11.e1" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e1" e2="DDI-PubMed.20508871.s11.e2" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e1" e2="DDI-PubMed.20508871.s11.e3" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e1" e2="DDI-PubMed.20508871.s11.e4" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e1" e2="DDI-PubMed.20508871.s11.e5" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e1" e2="DDI-PubMed.20508871.s11.e6" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e1" e2="DDI-PubMed.20508871.s11.e7" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e1" e2="DDI-PubMed.20508871.s11.e8" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e2" e2="DDI-PubMed.20508871.s11.e2" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e2" e2="DDI-PubMed.20508871.s11.e3" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e2" e2="DDI-PubMed.20508871.s11.e4" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e2" e2="DDI-PubMed.20508871.s11.e5" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e2" e2="DDI-PubMed.20508871.s11.e6" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e2" e2="DDI-PubMed.20508871.s11.e7" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e2" e2="DDI-PubMed.20508871.s11.e8" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e3" e2="DDI-PubMed.20508871.s11.e3" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e3" e2="DDI-PubMed.20508871.s11.e4" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e3" e2="DDI-PubMed.20508871.s11.e5" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e3" e2="DDI-PubMed.20508871.s11.e6" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e3" e2="DDI-PubMed.20508871.s11.e7" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e3" e2="DDI-PubMed.20508871.s11.e8" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e4" e2="DDI-PubMed.20508871.s11.e4" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e4" e2="DDI-PubMed.20508871.s11.e5" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e4" e2="DDI-PubMed.20508871.s11.e6" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e4" e2="DDI-PubMed.20508871.s11.e7" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e4" e2="DDI-PubMed.20508871.s11.e8" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e5" e2="DDI-PubMed.20508871.s11.e5" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e5" e2="DDI-PubMed.20508871.s11.e6" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e5" e2="DDI-PubMed.20508871.s11.e7" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e5" e2="DDI-PubMed.20508871.s11.e8" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e6" e2="DDI-PubMed.20508871.s11.e6" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e6" e2="DDI-PubMed.20508871.s11.e7" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e6" e2="DDI-PubMed.20508871.s11.e8" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e7" e2="DDI-PubMed.20508871.s11.e7" /><pair ddi="false" e1="DDI-PubMed.20508871.s11.e7" e2="DDI-PubMed.20508871.s11.e8" /></sentence><sentence text=" Among them, 54% showed dynamic and 34% kinetic interactions, 11% were categorized to be both and 76% displayed rapid-onset interactions" /><sentence text=" Moderate interactions were the most dominant (70%) phenomenon" /><sentence text=" Dynamic and kinetic interactions significantly differed with respect to the onset of interactions (P &lt; 0" /><sentence text="001)" /><sentence text=" A rather different pattern of drug-drug interaction exists in Iran, highlighting the need for a nationwide program on related education and a stronger focus on severe and rapid-onset interactions" /><sentence text=" Further studies warrant the need to explore high-risk patients" /><sentence text="" /></document>